bsm-41415M [Primary Antibody]
SARS-CoV-2 Nucleocapsid Protein Monoclonal Antibody (14B2D)
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Mouse

Target Protein: SARS-CoV-2 N protein

Clonality: Monoclonal

Isotype: IgG2b

Swiss Prot: P0DTC9

Purification: Purified by Protein G.

Storage Buffer: Aqueous buffered solution containing 0.01M PBS(pH7.4) with 0.1% Proclin300.

Storage Condition: Store at -20°C for 12 months.

Background: Coronaviruses are enveloped viruses with a positive-sense RNA genome and with a nucleocapsid of helical symmetry. Coronavirus nucleoproteins localize to the cytoplasm and the nucleolus, a subnuclear structure, in both virus-infected primary cells and in cells transfected with plasmids that express N protein. Coronavirus N protein is required for coronavirus RNA synthesis, and has RNA chaperone activity that may be involved in template switch. Nucleocapsid protein is a most abundant protein of coronavirus. During virion assembly, N protein binds to viral RNA and leads to formation of the helical nucleocapsid. Nucleocapsid protein is a highly immunogenic phosphoprotein also implicated in viral genome replication and in modulating cell signaling pathways. Because of the conservation of N protein sequence and its strong immunogenicity, the N protein of coronavirus is chosen as a diagnostic tool.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-1000)
ELISA(1:500-1000)
IHC-P(1:200-400)

Cross Reactive Species: Virus

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Lane 1: SARS-CoV-2 N protein(Cat# bs-41408P) at 50ng; Lane 2: SARS-CoV-2 N protein(Cat# bs-41408P) at 25ng; Lane 3: SARS-CoV-2 N protein(Cat# bs-41408P) at 5ng; Lane 4: SARS-CoV-2 N protein(Cat# bs-41408P) at 2ng ; Lane 5: SARS-CoV-2 N protein(Cat# bs-41408P) at 1ng;Lane 6: SARS-CoV-2 N protein(Cat# bs-41408P) at 0.5ng probed with SARS-CoV-2 N protein monoclonal Antibody, Unconjugated (bsm-41415M) at 1:1000 dilution and 4˚C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.